Mechanisms underlying hypertension caused by anti-VEGF therapies include diminished nitric oxide synthesis in the endothelium, increased peripheral vascular resistance, and decreased density in the microvasculature, with additional contributions of renal dysfunction to hypertension.[26] Among antihypertensive agents, angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, and non-dihydropyridine calcium channel blockers may be preferred over other drugs.[27] Diuretics are unlikely to be selected as a first-line agent due to diarrhea side effects of anti-VEGF therapies. The gene discussed is VEGFA; the disease is Hypertension.